C18 Ganglioside GM2-d3 (d18:1/18:0-d3) (ammonium salt)
(Synonyms: C18 GM2-d3, N-omega-CD3-Octadecanoyl monosialoganglioside GM2, Monosialoganglioside GM2-d3, N-Stearoyl Monosialoganglioside GM2-d3) 目录号 : GC46993A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
C18 Ganglioside GM2-d3 is intended for use as an internal standard for the quantification of ganglioside GM2 by GC- or LC-MS. C18 Ganglioside GM2 is a monosialylated ganglioside found in the mammalian brain where it is localized to the cell membrane.1 It accumulates in Tay-Sachs and Sandhoff disease, which are neurodegenerative disorders characterized by deficiency of lysosomal β-hexosaminidase A and B, respectively.2 Ganglioside GM2 disrupts the function of immune cells and, when used at a concentration of 25 µM, increases migration and invasion of SK-RC-45 cells with no effect on proliferation.3 [Matreya, LLC. Catalog No. 2051]
1.Schnaar, R.L.Gangliosides of the vertebrate nervous systemJ. Mol. Biol.428(16)3325-3336(2016) 2.Baek, R.C., Martin, D.R., Cox, N.R., et al.Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff diseaseLipids44(3)197-205(2009) 3.Kundu, M., Mahata, B., Banerjee, A., et al.Ganglioside GM2 mediates migration of tumor cells by interacting with integrin and modulating the downstream signaling pathwayBiochim. Biophys. Acta.1863(7 Pt A)1472-1489(2016)
| Cas No. | N/A | SDF | |
| 别名 | C18 GM2-d3, N-omega-CD3-Octadecanoyl monosialoganglioside GM2, Monosialoganglioside GM2-d3, N-Stearoyl Monosialoganglioside GM2-d3 | ||
| Canonical SMILES | OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@@]2([H])[C@@H]([C@@]([C@H]([C@H](O2)CO)O[C@]3([H])O[C@@H]([C@@H]([C@@H]([C@H]3NC(C)=O)O)O)CO)([H])O[C@]4(C([O-])=O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@@H]([C@H](O)CO)O)O4)O)O[C@H]1OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(CCCCCCCCCCCCCCCCC([2H])([2H])[2H])=O.[NH4+] | ||
| 分子式 | C67H117D3N3O26.NH4 | 分子量 | 1404.7 |
| 溶解度 | Chloroform:Methanol:Water (2:1:0.1): Soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.7119 mL | 3.5595 mL | 7.119 mL |
| 5 mM | 0.1424 mL | 0.7119 mL | 1.4238 mL |
| 10 mM | 0.0712 mL | 0.3559 mL | 0.7119 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。